Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049128 | 0.82 | ESR1 (0.83) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL27706512 | 0.82 | ESR1 (0.61) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL5161421 | 0.82 | ESR1 (0.61) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL7069762 | 0.79 | EPHX1 (0.42) | ESR1ESR2EPHX1CHRM1UBE2N | |
| SCHEMBL4677361 | 0.78 | ESR1 (0.85) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL27791494 | 0.76 | LMNA (0.55) | LMNAHSD17B10 | |
| SCHEMBL13103502 | 0.76 | ESR1 (0.54) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL27667714 | 0.76 | ESR1 (0.83) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL5156210 | 0.75 | ESR1 (0.61) | ESR1ESR2EPHX1LMNAHSD17B10 | |
| SCHEMBL27757470 | 0.75 | ESR1 (0.61) | ESR1ESR2EPHX1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | ESR1 944/4885ESR2 275/4885EPHX1 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.